论文部分内容阅读
目的明确三阴乳腺癌化疗疗效与TOP2A基因的关系。方法共入组97例晚期三阴性乳腺癌患者,测定TOP2A基因与各临床指标的关系,并比较给予TAC方案化疗的38例患者的药物疗效与TOP2A的联系。结果97例三阴性乳腺癌患者TOP2A基因表达情况与患者的年龄、月经状态、组织学分级、转移部位、Ki67增殖指数及PS评分无明显相关性,P值均>0.05,无统计学显著性差异。TAC方案组有效26例,无效12例,在有效的患者中,TOP2A基因呈中高表达的例数多,差异有统计学意义,χ2值=5.810,P值=0.016。结论 TOP2A基因表达与三阴性乳腺癌化疗疗效有关,表达越高,疗效越好,值得进一步研究。
Objective To clarify the relationship between the curative effect of TOP2A gene and the curative effect of triple negative breast cancer. METHODS: A total of 97 patients with advanced triple negative breast cancer were enrolled in this study. The relationship between TOP2A gene and various clinical parameters was analyzed. The efficacy of Top2A in 38 patients with TAC regimen was compared. Results There was no significant correlation between the expression of TOP2A gene and the age, menstrual status, histological grade, metastasis, Ki67 proliferation index and PS score in 97 patients with triple negative breast cancer (P> 0.05), with no significant difference . In TAC regimen group, 26 cases were effective and 12 cases were ineffective. Among the effective patients, the number of cases with high expression of TOP2A gene in the patients with high TAC was higher than that in the TAC group (χ2 = 5.810, P = 0.016). Conclusion The expression of TOP2A gene is related to the curative effect of triple negative breast cancer chemotherapy. The higher the expression of TOP2A gene, the better the curative effect is, and it deserves further study.